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Abstract
Background: The host’s response to infection is characterized by altered levels of neurotrophins and an influx of
inflammatory cells to sites of injured tissue. Progenitor cells that give rise to the differentiated cellular mediators of
inflammation are derived from bone marrow progenitor cells where their development is regulated, in part, by cues from
bone marrow stromal cells (BMSC). As such, alteration of BMSC function in response to elevated systemic mediators has the
potential to alter their function in biologically relevant ways, including downstream alteration of cytokine production that
influences hematopoietic development.
Methodology/Principal Findings: In the current study we investigated BMSC neurotrophin receptor expression by flow
cytometric analysis to determine differences in expression as well as potential to respond to NGF or BDNF. Intracellular
signaling subsequent to neurotrophin stimulation of BMSC was analyzed by western blot, microarray analysis, confocal
microscopy and real-time PCR. Analysis of BMSC Interleukin-6 (IL-6) expression was completed using ELISA and real-time
PCR.
Conclusion: BMSC established from different individuals had distinct expression profiles of the neurotrophin receptors,
TrkA, TrkB, TrkC, and p75NTR. These receptors were functional, demonstrated by an increase in Akt-phosphorylation
following BMSC exposure to recombinant NGF or BDNF. Neurotrophin stimulation of BMSC resulted in increased IL-6 gene
and protein expression which required activation of ERK and p38 MAPK signaling, but was not mediated by the NFkB
pathway. BMSC response to neurotrophins, including the up-regulation of IL-6, may alter their support of hematopoiesis
and regulate the availability of inflammatory cells for migration to sites of injury or infection. As such, these studies are
relevant to the growing appreciation of the interplay between neurotropic mediators and the regulation of hematopoiesis.
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Introduction
Neurotrophins are a family of proteins which are best
characterized by their modulation of survival, differentiation and
apoptosis of cells in the nervous system. This family includes NGF,
BDNF, neurotrophin 3 (NT-3), and neurotrophins 4/5 (NT-4/
5)[1]. Neurotrophins signal through the high-affinity tropomyosin
receptor kinase (Trk) receptors, TrkA, TrkB, TrkC, and the low-
affinity receptor, p75NTR, a member of the tumor necrosis factor
receptor family[1,2].
NGF is a survival factor essential for a large number of
neuronal and non-neuronal cell types. The importance of
neurotrophin signaling is highlighted by neurodegenerative
conditions such as Alzheimer’s disease, in which there is a
dysregulation of pathways modulated by neurotrophic fac-
tors[3,4]. In addition to its role in neurological pathways,
neurotrophin signaling has an impact on innate and adaptive
immunity[5]. Alteration of NGF has been documented in
autoimmune inflammatory diseases including multiple sclero-
sis[6], psoriasis[7], systemic lupus erythematosus[8] and rheuma-
toid arthritis[9]. Traumatic brain injury[10], neuroectodermal
tumors[11] and endocrine disorders[12] are a few examples of
many conditions also associated with increased neurotrophins. A
positive correlation between NGF level and allergic asthma,
airway hyperactivity, total IgE and the number of eosinophils in
the serum has also been noted[13]. These observations suggest
that neurotrophins may mediate hematopoietic responses to
several clinically relevant conditions. Importantly, NGF has the
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potential to act systemically on distant organs, including the bone
marrow which serves as the primary site of postnatal hemato-
poiesis[14,15].
BMSC provide the structural and physiological support for
hematopoietic cell survival, proliferation and differentiation.
Resident stem and immature hematopoietic progenitor cells
mature under the influence of the bone marrow microenviron-
ment to functional, mature cells of diverse lineages[14,15]. As
such, exposure of this microenvironment to circulating neuro-
trophins, cytokines and growth factors has the potential to alter
its function, resulting in the generation of hematopoietic
populations that are markedly different than those in healthy
individuals.
In the current study, a cytokine that was consistently and
significantly increased in BMSC exposed to NGF or BDNF was
Interleukin-6 (IL-6). IL-6 is a multifunctional cytokine[16]
modulated by other factors including IL-1, TNF-a, growth factors,
hormones, and viral or microbial products[17–19]. Dysregulation
of IL-6 production has been reported in the pathogenesis of several
autoimmune diseases including rheumatoid arthritis, systemic-
onset juvenile chronic arthritis, autoimmune encephalomyelitis,
psoriasis, antigen-induced arthritis, and Systemic Lupus Erythe-
matosus[16,20–22]. IL-6 is a critical factor for hematopoiesis
through regulation of the entry of hematopoietic stem cells into the
cell cycle, proliferation of cells committed to the myeloid and
lymphoid lineage, and maturation of B-cells into antibody
producing cells[16,23–26]. Increased IL-6 expression in transgenic
mice results in massive polyclonal plasmacytosis and malignant
plasmacytoma[26]. In contrast, a reduction in hematopoietic
progenitor cell support has been reported by IL-6 deficient bone
marrow stromal cells[27]. These observations suggest that changes
in IL-6 levels could impact on the development of hematopoietic
populations available to participate in inflammatory responses
with the novelty of our current study derived from consideration of
the potential of systemic neurotrophic factors to modulate IL-6 in
the marrow microenvironment through direct stimulation of
BMSC.
Depending upon the cellular context, IL-6 transcription has
been documented to be influenced by both NF-kB and MAPK
(mitogen-activated protein kinase) cascades subsequent to NGF
stimulation[28,29]. Studies have shown that NGF activates NF-
kB in rat pheochromocytoma PC12 cells[30]. NF-kB is
sequestered in the cytoplasm by the IkB family of proteins
which become phosphorylated, and degraded by the protea-
some with subsequent NF-kB translocation to the nucleus[31].
As a transcription factor involved in the control of inflammatory
responses, cellular growth, and apoptosis[31], NF-kB is involved
in the pathology of several diseases, including cancers, arthritis,
chronic inflammatory bowel disesse, asthma and neurodegen-
erative diseases[32–36]. Neurotrophin stimulation of the MAPK
pathway has been documented in the PC12 cell line[37], dorsal
root ganglia, and transient receptor potential vanilloid 1
(TRPV1) (the capsaicin receptor) model[38]. Activation of the
TrkA receptor by NGF in airway smooth muscle cells also
leads to activation of the MAPK cascade including p38
MAPK, and extracellular-regulated protein kinase 1/2
(ERK1/2)[39]. Following stimulation, the MAPK family of
proteins activate several downstream factors involved in
regulating inflammation[37–39].
Based on the diverse set of pathologic conditions associated with
dysregulated neurotrophic factors, many of which involve
inflammation as a central feature, we investigated the effects of
NGF and BDNF on BMSC function as a critical influence on
regulation of hematopoietic cell development.
Results
BMSC have distinct expression profiles for TrkA, TrkB,
TrkC and p75NTR
To determine the expression pattern of neurotrophin receptors
by BMSC, flow cytometry analysis of BMSC with antibodies
specific for, TrkA, TrkB, TrkC and p75NTR was performed. While
the levels of expression for a given receptor varied between stromal
lines derived from different individuals, all BMSC lines used in this
study expressed both the high and low affinity receptors to respond
to neurotrophins (Figure 1).
BMSC demonstrate Akt phosphorylation following NGF
or BDNF exposure
Activation of Akt occurs in response to a variety of stimuli, and
relevant to the current study, is a well documented consequence of
neurotrophin stimulation[40]. Therefore, while not a investigative
focus in this work, the phosphorylation of Akt was utilized simply
as a read-out to determine if BMSC could respond to
neurotrophin binding to the Trk receptors. Phosphorylation of
Akt occurred rapidly following BMSC exposure to 100 ng/ml of
NGF or BDNF. NGF treated BMSC Akt phosphorylation was
detected as early as 5 minutes with the peak signal occurring at 30
minutes. Phosphorylated Akt began to diminish by 1 hour, and
minimal signal was detected after 6 hours of exposure to NGF. In
BDNF treated cells, peak phosphorylation of Akt occurred at 5
minutes and gradually diminished over 6 hours (Figure 2).
Exposure to NGF or BDNF increases IL-6 gene expression
in the BMSC
To investigate the cytokine pattern of BMSC exposed to
neurotrophic factors, RNA isolated from BMSC exposed to NGF
and BDNF was analyzed by microarray as described. While many
genes were increased, and fewer decreased, following NGF or
BDNF exposure, with a cut-off of 3 fold-change compared to
untreated controls, Fibroblast Growth Factor-2 (FGF2) and IL-6
emerged as those genes markedly upregulated following NGF or
BDNF treatment in this panel (Figure 3A–B). In addition, the
BDNF receptor (NTRK2) and CRH1 gene expression increased
following NGF exposure, but did not meet the threshold cutoff in
cells exposed to BDNF. IL-6 was chosen for further investigation
to determine the signaling pathway that may underlie altered
expression based on its well characterized role in hematopoiesis.
To validate our IL-6 microarray data, relative transcript levels
were determined by quantitative real-time PCR. Consistent with
the microarray data, IL-6 mRNA increased in BMSC after
exposure to both NGF and BDNF (Figure 3C-D).
BMSC exposed to NGF or BDNF demonstrate increases in
IL-6 protein consistent with gene expression changes
To evaluate effects of NGF or BDNF on IL-6 protein, BMSC
were serum deprived (1% FBS) for 24 hours and subsequently
exposed to 100 ng/ml of NGF or BDNF for 24 or 48 hours in
triplicate. An IL-6 ELISA was performed on the supernatant
collected from each time point to determine changes in the
production of IL-6 protein. Consistent with the up-regulation of
IL-6 message, exposure of BMSC to NGF and BDNF increased the
level of IL-6 protein (Figure 4). To determine the optimal
concentration of neurotrophins needed to induce NGF or BDNF
signaling, resulting in IL-6 protein increase, a dose response curve
was completed, using an IL-6 ELISA with doses of neurotrophins
ranging from 0–100 ng/ml. AMTT assay was used to determine the
concentrations of neurotrophins used were not toxic to the BMSCs
Neurotrophins Regulate IL-6
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(data not shown). To determine if there is a role for the sIL-6R in our
model, BMSC were left untreated or stimulated with NGF or BDNF
(10–100 ng/ml) for 24 hours and a sIL-6R ELISA was completed.
There was no detectable sIL-6R present in the untreated cells or in
those cells treated with NGF or BDNF (data not shown).
Neurotrophins do not induce NF-kB signaling in BMSC
In neurons, it has been established that neurotrophin stimula-
tion activates signaling through NF-kB[30]. Additionally, NF-kB is
a known transcription factor for IL-6[28]. Using immunofluores-
cence, we determined whether exposure of BMSC to neurotro-
phins induced nuclear translocation of the p65 subunit of NF-kB.
BMSC (one cell line) were exposed to either NGF or BDNF.
Subsequent to NGF or BDNF exposure, no nuclear translocation
of the NF-kB p65 subunit was noted. In contrast, rTNF-a, which
was used as a positive control, induced rapid translocation of the
p65 subunit from the cytoplasm to the nucleus in the BMSC
(Figure 5A). To confirm the lack of p65 translocation to the
nucleus with NGF stimulation, BMSC were left untreated or
treated with NGF (100 ng/ml) for 30 min. Following treatment,
cellular fractionation was completed and the fractions analyzed by
western blot with p65 specific antibodies. There was no detectable
p65 in the nuclear fraction of untreated or NGF treated cells, while
p65 was readily detected in the cytoplasmic fraction (Figure 5B).
GAPDH was used as a fraction contamination control (data not
shown).
NGF and BDNF induce MAPK ERK1/2 signaling pathway
Stimulation of neuronal TrkA with NGF has been shown to
activate the MAPK components ERK1/2 and p38 MAPK[39].
To evaluate the role of neurotrophin induced MAPK signaling
in BMSC, we analyzed phosphorylation of ERK1/2 as a read
out of MAPK activation following BMSC exposure to NGF or
BDNF. Phosphorylation of ERK occurred rapidly and tran-
siently in both NGF and BDNF treated groups while no
phosphorylation was detected in untreated control cells
(Figure 6).
MAPK ERK1/2 pathway inhibitors blunted IL-6 production
following NGF or BDNF exposure
As shown previously (Figure 4), treatment with NGF or BDNF
increased IL-6 protein in BMSC supernatants. While there was
variation in the level of IL-6 protein induction with neurotro-
phin treatment alone (Figure 4 and Figure 7), the overall
increase in IL-6 protein with NGF or BDNF treatment remains
consistent. The increase in IL-6 protein with NGF or BDNF
stimulation without any inhibitors was statistically significant
(p = .001 for NGF and p= .002 for BDNF) (Figure 7). To further
investigate the role of ERK1/2 and p38 pathway in neurotro-
phin induction of IL-6, specific inhibitors targeting both
pathways were utilized as discussed in methods. Pre-treatment
of BMSC with U0126 and SB 203580 in concentrations held
low enough to maintain specificity of inhibition resulted in
approximately a 50% decrease of IL-6 upon exposure to NGF or
BDNF (Figure 7). To investigate the role of the Akt pathway in
neurotrophin induction of IL-6, BMSC were pre-treated as
described above with Akt VIII, a specific Akt inhibitor, for 2 hrs
prior to stimulation with NGF or BDNF. Akt inhibition did not
decrease IL-6 protein detected in BMSC supernatants (data not
shown).
Figure 1. BMSC express neurotrophin receptors. BMSC established from different individuals were stained for high affinity receptors (A) TrkA,
(B) TrKB, (C) TrkC and the low affinity receptor (D) p75NTR with specific antibodies followed by flow cytometric evaluation. BMSC expressed distinct
profiles of neurotrophin receptors. Isotype matched controls are indicated by the solid histogram.
doi:10.1371/journal.pone.0009690.g001
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Discussion
The purpose of this study was to determine if BMSC gene
expression is responsive to NGF or BDNF as a means by which
neurotrophic factors may indirectly influence hematopoiesis.
Many in vivo and in vitro studies have investigated the role of
neurotrophins in hematopoiesis. NGF has been demonstrated as
an important factor for hematopoietic colony growth and
differentiation[41]. Previous work documents its ability to directly
influence proliferation, differentiation, and maturation of myeloid
progenitors along with induction of migration, survival and
activation of mature hematopoietic cells[42–44]. NGF is also a
chemotactic stimulus for human leukocytes and macrophag-
es[45,46]. Fewer studies have focused specifically on the response
of BMSC to neurotrophic factors as the mechanism by which
NGF or BDNF may indirectly influence hematopoiesis. However,
there have been previous reports that document the expression of
NGF receptors on BMSC[47] as well as the capacity of BMSC to
produce and respond to NGF during normal hematopoiesis[48].
The role of BDNF on immune function and hematopoietic cell
development is not as well defined as NGF, although impaired B
cell development in bone marrow of BDNF deficient mice has
been reported[49].
An earlier study demonstrated expression of high affinity
neurotrophin receptors by rat marrow stromal cells [50]. In the
current study, we have demonstrated expression of both high and
low affinity receptors for neurotrophins by human BMSC, with
their level of expression varying between BMSC donors
(Figure 1A–D). While in some settings signaling through the low
affinity receptor p75 following NGF exposure can result in
apoptosis[51], in the presence of TrkA the signals are predomi-
nantly reported to be anti-apoptotic[52]. Co-expression of both
high and low affinity receptors by human BMSC appear to have
favored the anti-apoptotic effects of neurotrophin signaling. The
neurotrophin receptors are functional as demonstrated by Akt-
phosphorylation following stimulation of BMSC by NGF and
BDNF (Figure 2A–B). Phosphorylation of Akt, while it may
influence survival of BMSC consistent with its role in several
settings, was not being investigated in its survival context in our
model. Rather, as a well characterized downstream target of
neurotrophic signaling it was merely monitored as a measure of
functionality of receptors in the absence of a clearly defined signal
more immediately stimulated by NGF or BDNF in BMSC.
Through microarray analysis we demonstrated that cytokine
gene expression by BMSC changes in response to NGF or BDNF
exposure (Figure 3A, B). Any focused panel of gene expression
analysis is, by design, not an exhaustive evaluation of all the
potential targets that respond to any stimulus. As such, we chose a
focused evaluation, and subsequently targeted IL-6 for follow up
based on its diverse involvement in innate immunity, hematopoiesis,
and inflammatory responses[16]. Consistent with the microarray
data, IL-6 gene and protein expression increased after exposure to
both NGF and BDNF as determined by real-time PCR and ELISA
respectively (Figure 3C, D and Figure 4). In addition to IL-6, FGF2
was increased more than three-fold that of matched controls by both
BDNF and NGF. Previous reports have indicated that elevated
FGF2 decreased both stromal cell derived factor-1 (SDF-
1;CXCL12) mRNA and protein in vivo and also diminished the
Figure 2. BMSC Akt phosphorylation increases following NGF or BDNF exposure. Following treatment with NGF or BDNF, BMSC were
lysed and protein was resolved by SDS-PAGE and transferred to nitrocellulose membranes. (A) Membranes were probed with antibodies specific for
phospho-Akt and total Akt; GAPDH was used as a lane loading control. (B) Densitometry demonstrates an increase in phospho-Akt:Total Akt
following NGF or BDNF exposure.
doi:10.1371/journal.pone.0009690.g002
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capacity of BMSC to support the expansion of peripheral blood
derived stem cells[53]. Uniquely, the Trk B receptor (NTRK2) was
increased by NGF, but not BDNF, with the increase reaching our
threshold cut-off of three times that of untreated cells. This increase
suggests a potential synergistic relationship between these two
neurotrophic factors in which an NGF increase may position BMSC
cells to more robustly respond to BDNF through modulation of
TrkB receptor expression. Consequently, subtle increases in
circulating BDNF may have pronounced signaling potential when
NGF increases have occurred previously.
The significant role of IL-6 in inflammation has been
demonstrated by the diminished ability of IL-6 knockout mice to
respond to environmental air pollutants exposure compared to
wild-type control[54]. Of specific relevance to the current study,
IL-6 overproduction in transgenic animals resulted in an increase
in the number of megakaryocytes, plasmacytosis formation and
extramedullary hematopoiesis[26,55], suggesting elevated IL-6
subsequent to circulating NGF or BDNF may contribute to
dysregulated immune function. Of note, all reports are not
consistent with a clear inflammatory response subsequent to
increased NGF, with a recent study suggesting that NGF may, in
fact, have anti-inflammatory actions via its regulation of calcitonin
gene-related peptide (CGRP) in monocytes[56]. This recent work
highlights the necessity of interpreting data within the confines of
the specific model being investigated.
Figure 3. NGF or BDNF changes the gene expression profile of BMSC and increases IL-6 mRNA. BMSC were treated with 100 ng/ml of (A)
NGF or (B) BDNF for 18 hours. The cells were collected, RNA was isolated, and microarray analyses were performed. Graphs summarize the panel of
gene expression changes in the BMSC treated with NGF or BDNF compared to untreated control cells. BMSC were treated with 100 ng/ml of (C) NGF
or (D) BDNF for 2, 4 and 8 hours. The cells were collected, RNA was isolated and real time PCR was performed with the one-step QuantiTech SYBR
Green kit as instructed by the manufacturer. BMSC IL-6 expression in response to NGF or BDNF exposure compared to untreated control cells is
shown. Expression was normalized to the housekeeping gene GUSB. Statistical analysis was completed by ANOVA (P#0.0001) with significance
indicated by an asterisk.
doi:10.1371/journal.pone.0009690.g003
Figure 4. BMSC treatment with NGF or BDNF increases IL-6
protein. BMSC were exposed to 100 ng/ml of NGF or BDNF for 24 and
48 hours. The supernatant was then collected and an IL-6 ELISA was
performed. An increase in BMSC IL-6 protein was noted in all treatment
groups. Statistical analysis was completed by ANOVA (P#0.01) with
significance indicated by an asterisk.
doi:10.1371/journal.pone.0009690.g004
Neurotrophins Regulate IL-6
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Our data do not rule out the possibility of NGF or BDNF acting
on gene expression in BMSC through one, or several, intermediate
factors. Increased expression or release of Substance-P following
neurotrophic stimulation of cells has been described in diverse
settings documenting its important role in the hematopoietic-
neuro-immune axis in inflammation, as well as normal and
malignant hematopoiesis[57–62]. Relevant to our model, Sub-
stance-P has been shown to participate in upregulation of
Figure 5. Neurotrophins do not induce NF-kB signaling in
BMSC. BMSC were treated with 100 ng/ml of NGF, BDNF, or TNFa for 5,
30 and 60 minutes. Following treatment, BMSC were fixed and probed
with antibodies specific for NFkB p65 or its matched isotype control.
Analyses of samples by confocal microscopy indicate cytoplasmic p65
in untreated control and translocation of p65 to the nucleus upon
stimulation with a known positive stimulus, TNF-a (A). The subcellular
localization of p65 did not change in response to NGF or BDNF.
Representative images from 30 minutes exposure to stimuli are shown
(original magnifications640). (B) BMSC were left untreated or treated
with NGF (100 ng/ml) for 30 min. and subcellular fractionation and
western blot analysis completed with p65 specific antibodies.
Treatment of BMSC with NGF did not change the subcellular
localization of p65.
doi:10.1371/journal.pone.0009690.g005
Figure 6. BMSC demonstrate activation of MAPK ERK following
NGF or BDNF exposure. Following treatment with100 ng/ml of NGF
or BDNF, BMSC were lysed and protein was resolved by SDS-PAGE and
transferred to nitrocellulose membranes. (A) Membranes were probed
with antibodies specific for phospho ERK1/2 and total ERK; GAPDH was
used as a lane loading control. (B) Densitometric quantitation of
increase in phosphorylated Erk:Total Erk following NGF or BDNF
exposure.
doi:10.1371/journal.pone.0009690.g006
Figure 7. ERK and p38MAPK pathway inhibitors blunted IL-6
protein increase during NGF or BDNF exposure. A MEK1/2
inhibitor, U0126, and p38 MAPK inhibitor SB 203580 was introduced to
BMSC cultures 2 hours prior to NGF or BDNF exposure. BMSC were then
exposed to 100 ng/ml of either NGF or BDNF for 24 hours and an IL-6
ELISA was performed on collected supernatants. BMSC pre-treated with
U0126 or SB 203580 demonstrated greater than 50% decrease in IL-6
protein upon exposure to NGF or BDNF. Statistical analysis was
completed by ANOVA (P#0.01) with significance indicated by an
asterisk. Groups that included inhibitor were compared to matched
group with no inhibitors. BMSC treated with NGF or BDNF without
inhibitors had a significant increase in IL-6 protein (p = .001 and p= .002
respectively as determined by a Student’s t-test (#)).
doi:10.1371/journal.pone.0009690.g007
Neurotrophins Regulate IL-6
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inflammatory cytokines in fibroblastic cells[63,64] and more
recently in a model of increased IL-6, IL-1b, and TNF-a in a
model of burn-induced lung injury[65]. These reports raise the
possibility that Substance-P may be an intermediate between
neurotrophic factor exposure and altered gene expression in
BMSC as well which has not been investigated. Studies that
include targeted knock-out of Substance-P will be intriguing, and
are required to determine if it is a required mediator of signaling in
BMSC. However, regardless of outcome, the biological signifi-
cance remains that functional changes in a critical component of
the marrow microenvironment, BMSC, can be elicited by
circulating NGF or BDNF.
Different reports suggest several pathways mediate IL-6
induction and the immunomodulatory effects of neurotrophins
based on the stimulus and cell type. Our study demonstrated
phosphorylation of ERK1/2 MAPK (Figure 6A, B), with no
nuclear translocation of NF-kB detected (Figure 5) following NGF
or BDNF treatment of BMSC. Furthermore, we observe that
ERK1/2 and p38 MAPK pharmacological inhibitors (U0126 and
SB203580) significantly reduced IL-6 production by BMSC during
exposure to NGF or BDNF (Figure 7). This observation is
consistent with a recently reported model that included LPS
stimulated BMSC in which SB-203580 inhibited IL-6 and IL-11
mRNA expression[66]. Our data suggest ERK and p38 MAPK
pathways are required for optimal BMSC IL-6 induction by NGF
and BDNF, with these pathways likely involved in baseline
expression of IL-6 as a reduction in steady state expression was
noted with both inhibitors in the absence of any neurotrophic
stimulation. The inhibition noted following stimulation was
approximately 50% suggesting that other pathways are also
involved in NGF and BDNF stimulated IL-6 production. While a
dose response of increased inhibitor concentration could be
completed to determine if more pronounced inhibition can be
achieved, the approach is not valid based on the loss of specificity
that will occur at higher doses. Therefore, experiments were
completed with the concentration limited to generate meaningful
results.
Collectively these data suggest BMSC can be modulated by
neurotrophins in a manner consistent with influence on hemato-
poietic cell proliferation and differentiation, reflected by a
significant IL-6 increase in this study. As such, neurotrophins
are positioned to regulate the availability of inflammatory cells
derived from the marrow, through both direct[41–44] and indirect
mechanisms. Taken together, our data suggest a central role for
neurotrophins in the inflammatory process subsequent to infection
and identify bone marrow stroma as a novel target for these
factors. Further, this study broadens the context in which we
should consider the consequences of dysregulated neurotrophin
expression.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of West Virginia University. All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Cell culture and reagents
P163, P164, PED299, PED604, PED62304 and GPBM 1–32
primary human bone marrow stromal cells (BMSC) were derived
from consenting donors (written consent) with the approval of the
West Virginia University Institutional Review Board. Establish-
ment of BMSC and their characterization have been previously
described in detail[67]. Because the characteristics of BMSC can
be influenced by preparative regimens, all lines were established
identically and evaluated at comparable passage number in the
experiments presented. BMSC were maintained in Minimum
Essential Medium, Alpha (a-MEM) (Mediatech, Manassa, VA)
supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Pittsburgh, PA), 2 mM L-glutamine (Mediatech) 100 mg/ml
streptomycin, 100 IU/ml penicillin (Sigma, St. Louis, MO), and
561025 M 2-b mercapthanol (Sigma), at 37uC in 6% CO2. Of
note, the concentration of 2- b mercapthanol used is less than that
published as having the potential to stimulate cells to neural
differentiation[68]. The adherent, fibroblastic BMSC utilized in all
of our studies constitutively express VCAM-1, Fibronectin, SDF-1
(CXCL-12), VEGF, Thrombospondin and a variety of cytokines
that influence both lymphoid and myeloid cell survival and
expansion.
Flow cytometric analysis
Six different BMSC lines were grown to confluence (,106
cells), trypsinized, fixed in 10% formaldehyde for 30 minutes, and
subsequently permeabilized in 70% EtOH for 30 minutes on ice.
To reduce non-specific antibody binding, BMSC were blocked in
3% BSA in PBS for 15 minutes and subsequently incubated with
1 mg per sample of rabbit polyclonal TrkA or TrKB, goat
polyclonal p75NTR specific antibodies from Santa Cruz Biotech-
nology,Inc. (Santa Cruz, CA). For detection of TrkC, TrkC-PE
(FAB373P) and isotype control goat IgG-PE were acquired from
R&D systems (Minneapolis, MN). The additional isotype control
antibody, rabbit IgG, was purchased from Southern Biotechnol-
ogy (Birmingham, AL). Primary antibody binding was detected
by incubation with 1 mg per sample fluorescein isothiocyanate
(FITC)–conjugated goat anti-rabbit (Santa Cruz Biotechnology)
for Trk A and TrkB and FITC–conjugated rabbit anti-goat
IgG(H+L) (Southern Biotechnology) for p75NTR. Data were
acquired by counting 10000 events and analyzed using
FACSCalibur (BD Biosciences, San Jose, CA). One representa-
tive cell line from the six lines examined was chosen for
completion of the remaining experiments in the manuscript
unless indicated.
Western blot analysis
Confluent BMSC were treated with 100 ng/ml mouse NGF
2.5 S (Roche Applied Science) or recombinant human BDNF
(Invitrogen, Carlsbad, CA) for 5 minutes, 30 minutes, 1 hour
and 6 hours. Following treatment, BMSC were lysed in
complete cell lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1% Triton X-100, 0.25% Na-deoxycholate, 1 mM
EDTA, and 1 mM NaF, 1 mM DTT, 1 mM PMSF, 1 mM
activated Na3VO4, 1 mg/mL aprotinin, 1 mg/mL leupeptin, and
1 mg/mL pepstatin) on ice for 15 minutes. Following centrifu-
gation at 20,0006g for 15 minutes, supernatants were collected
and protein concentration was determined using the bicincho-
ninic acid protein assay (BCA). Proteins were resolved on SDS-
PAGE and transferred to nitrocellulose membranes (Schleicher
& Schuell Bioscience, Keene, New Hampshire). Membranes
were blocked in TBS/5% nonfat dry milk/0.1% Tween-20 at
room temperature for 1 hour, and probed with the primary
antibodies rabbit anti-phospho-Akt (Ser473) or rabbit anti-Akt,
(Cell Signaling Technology, Inc, Danvers, MA). Additional
antibodies included rabbit Erk 1/2 (Cell Signaling Technolo-
gies) and anti-phospho ERK1/2 purchased from Promega
Corporation (Madison, WI). Mouse anti-GAPDH (Fitzgerald
Industries International, Concord, MA) was used as a lane
Neurotrophins Regulate IL-6
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9690
loading control. Washes were in TBS/0.1% Tween-20 following
incubation with horseradish peroxidase-conjugated secondary
antibodies. Luminol (Santa Cruz Biotechnology) generated
signal was detected on x-ray film. Densitometric analysis was
performed using the Fotodyne imaging system with Foto/
Analyst version 5.00 software (FOTODYNE Inc., Hartland,
WI) for image acquisition, and TotalLab version 2005 software
for analysis.
Cellular Fractionation and Western Blot Analysis
BMSC were left untreated or treated with NGF (100 ng/ml) for
30 min. Cells were trypsinized, pelleted and cellular fractionation
was completed using the NE-PER cytoplasmic and nuclear
extraction kit (Pierce Biotechnology, Rockford, IL). Protein
concentration was determined using the bicinchoninic acid
(BCA) protein assay (Pierce Biotechnology). Cytoplasmic and
nuclear proteins were resolved on SDS-PAGE gels and transferred
to nitrocellulose membranes. Membranes were blocked with 5%
nonfat dry milk/1X TBS/0.1% Tween-20 and probed with a
mouse monoclonal p65 specific antibody. After incubation with
anti-mouse HRP- conjugated secondary antibody, the signal was
visualized using Immobilon chemiluminescence reagents (Milli-
pore, Billerica, MA).
RNA Isolation
Total RNA was isolated from three BMSC lines treated with
NGF or BDNF (100 ng/ml) using the Qiagen RNeasy Mini kit
following the recommendations of the manufacturer (Qiagen,
Valencia, CA). Pelleted BMSC were lysed by centrifugation
through QIA shredder spin columns and RNA was treated with
1U DNAse for 15 minutes at 24uC. Samples were quantified at
260 nm (GENESYS-10UV, Spectronic, Unicom) and protein
contamination determined by evaluation at 280 nm.
Microarray analysis
Gene expression profiles of BMSC were assessed using the
Human Neurotrophin and Receptor Gene Array HS-018 (Super-
Array, Frederick, MD) as a representative, but not exhaustive,
approach for screening of NGF or BDNF induced changes in gene
expression. BMSC RNA from untreated control and NGF or
BDNF treated cells was converted to biotinylated cDNA using the
Ampolabeling-LPR kit (SuperArray). Membranes were hybridized
with cDNA probes overnight at 60uC with continuous agitation at
5–10 r.p.m and then washed as recommended by the manufac-
turer. Signal was detected on X-ray film with images scanned and
analyzed with GEArray Expression analysis suite software (Super-
Array). Signal intensities were normalized to GAPDH and beta-actin
on each membrane. Only those genes having a 3 fold or higher
change in expression were examined (GEO accession number
GSE18537).
Real-time PCR
To determine relative IL-6 expression, real-time PCR was used
to validate data from microarray experiments. The one-step
QuantiTect SYBR Green RT-PCR Kit (Qiagen) was used as
recommended by the manufacturer. All reactions were performed
in triplicate using 80 ng of RNA per reaction, IL-6 gene primers
(#PPH08958A; SuperArray) or the housekeeping gene GUSB
(beta glucuronidase) (Real Time Primers, Elkins Park, PA).
Amplifications were completed using a 7500 real-time PCR
system (Applied Biosystems, Foster City, CA). Amplification
conditions included 50uC for 30 minutes, 95uC for 15 min, 45
cycles of 94uC for 15 seconds, 55uC for 30 seconds, and 72uC for
45 seconds. The relative quantitative method (DDCT) was used to
evaluate gene expression in experimental and control cells for each
gene examined[69].
ELISA
BMSC were cultured in a 96-well plate and allowed to grow
to confluence. Primary BMSC exhibit contact inhibited grown
upon reaching confluence and are grown to confluence to
prevent any proliferation following treatments. When the
BMSC were confluent, they were serum deprived (1% FBS)
for 24 h before treatment with 100 ng/ml NGF or BDNF for 24
or 48 hours. Supernatants were collected and a human IL-6
ELISA completed (eBioscience, San Diego, CA) with 1/20
dilution of supernatants as recommended by the manufacturer.
For experiments in which the effects of MEK and MAPK
inhibition were studied, 20 mM of the MEK inhibitor U0126 or
10 mM of the p38 MAPK inhibitor SB 203580 (Promega) were
added 2 hours before treatment with NGF or BDNF in select
wells. Integrity of cell layers was confirmed prior to collection of
supernatants. An MTT assay was completed to show that
neurotrophin treatment did not induce proliferation or cell
death (data not shown).
Immunostaining and confocal microscopy
BMSC were grown to confluence on glass coverslips and treated
with 100 ng/ml NGF, BDNF or rTNF-a (R&D Systems), for 5, 30
and 60 minutes. Following treatment, BMSC were rinsed in
phosphate-buffered saline (PBS) and fixed in 4% formaldehyde at
room temperature for 30 minutes, followed by rinsing and fixing in
acetone for 10 minutes. Permeabilization of cells was completed
with 0.5% Triton X-100 for 30 minutes. Nonspecific antibody
binding was blocked by incubation of BMSC for 30 minutes in
PBS/5% BSA. NF-kB localization was evaluated by incubation of
BMSC with 2 mg/coverslip of mouse anti-human monoclonal NF-
kB p65 (Santa Cruz Biotechnology) in PBS/5% BSA for 1 hour.
Subsequently, Alexa Fluor 555 donkey anti-mouse IgG(H+L)
(Invitrogen), was applied at a 1 mg/coverslip for one hour.
Coverslips were then inverted on slides and mounted with Prolong
Gold antifade reagent with 4, 6 diamidino-2-phenylindole (DAPI)
(Invitrogen). Images were collected using a Zeiss LSM510 confocal
on an AxioImager Z1 microscope (Carl Zeiss) with a 405-diode
laser to excite DAPI and a 543 HeNe laser to excite the
AlexaFluor 555-labeled secondary antibody. Cells were visualized
using a 406/1.30 oil objective. All confocal images were adjusted
equally using Adobe Photoshop.
Statistical analysis
Data presented were expressed as mean 6 SEM for triplicate
samples. Statistical analysis was performed by ANOVA (p#0.01
determined as significant) and Student t-test (p#0.01 determined
as significant).
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